| |
Focused on accelerating gene and cell therapy from clinical to commercial, OcyonBio built two processing facilities in Puerto Rico. See how the company is now benefiting from the island's highly skilled talent, tax benefits & much more. 
|
|
Today’s Big NewsMar 6, 2024 |
| By Gabrielle Masson Alumis has reeled in an eye-watering $259 million series C, financing that will support a pipeline of oral therapies designed to tackle immune dysfunction and help launch a phase 3 psoriasis trial for lead asset ESK-001. |
|
|
|
By Conor Hale The agency’s green light allows adults 18 years and older who are not taking any insulin therapies to purchase the system without a prescription—a group that includes about 25 million people living with Type 2 diabetes in the U.S., according to the company. |
By Angus Liu AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing £650 million into the Big Pharma’s home country. |
By Max Bayer Gilead and Merus are linking up in a new research and licensing deal for the latter's trispecific T-cell engages. Gilead is handing over $56 million in upfront cash plus a $25 million equity investment to jumpstart the deal. |
|
Wednesday, March 13, 2024 | 11am ET / 8am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion! 
|
|
By Zoey Becker The company, which makes Myfembree, Gemtesa and Orgovyx, previously let go of 500 staffers last summer. |
By Conor Hale The drugmaker has re-upped ties with the former Fierce 15 winner, whose Precivity blood tests detect tau and beta amyloid proteins in the bloodstream. |
By Ben Adams In February's top 10 pharma ad spending list, AbbVie claimed both the first and second spots, a trend it has maintained for much of the past 12 months, although the positions of its drugs were reversed. |
By Zoey Becker The World Health Organization (WHO)'s latest HIV Drug Resistance report showed that some patients are developing resistance to Tivicay, which has been recommended as a preferred treatment since 2018. |
By Annalee Armstrong Early results show that a weekly combination of Merck’s islatravir and Gilead’s approved HIV med Sunlenca maintained a high rate of viral suppression in patients with HIV, but just one patient so far has met the primary endpoint that measured viral load. |
By Nick Paul Taylor Merz Aesthetics has enlisted another celebrity to tackle the skyscraper-sized challenge of muscling in on the anti-wrinkle market. The actor and musician Demi Lovato is the latest star to partner with Merz on the multiyear “Beauty on Your Terms” campaign the drugmaker is running in support of Xeomin. |
By Conor Hale An analysis of real-world data by Abbott showed that the rise of GLP-1 medicines doesn’t necessarily have to take a major bite out of medtech sales, as combining the injections for diabetes and weight loss with continuous glucose monitors can help further improve blood sugar control. |
By Kevin Dunleavy In its continuing expansion blitz, Almac has completed new facilities at its headquarters in Craigavon, Northern Ireland, which will expand the capacity of the CDMO to package commercial products and to manufacture peptides. |
Fierce podcasts Don’t miss an episode |
| The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This week on "The Top Line," Fierce Pharma’s Angus Liu talks with regulatory experts to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line. |
|
|---|
|
|
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
